ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

医学 乳腺癌 家庭医学 医学物理学 癌症 肿瘤科 重症监护医学 内科学
作者
P. Tarantino,Giulia Viale,Michael F. Press,Xin Hu,Frédérique Penault‐Llorca,A. Bardia,Anna Batistatou,H.J. Burstein,L.A. Carey,Javier Cortés,C. Denkert,V. Diéras,William Jacot,A. Koutras,Alizée Lebeau,S. Loibl,Shanu Modi,M.F. Mosele,Elena Provenzano,Giancarlo Pruneri
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34 (8): 645-659 被引量:256
标识
DOI:10.1016/j.annonc.2023.05.008
摘要

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from nine different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer; and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This article presents the developed statements, including findings from the expert panel discussions, expert opinion, and a summary of evidence supporting each statement.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
啊七发布了新的文献求助10
1秒前
2秒前
4秒前
5秒前
英姑的应助被slk采纳,获得10
5秒前
华无剑的应助被zhe采纳,获得10
5秒前
空集发布了新的文献求助10
6秒前
小蘑菇的应助被李建勋采纳,获得10
6秒前
6秒前
6秒前
核桃发布了新的文献求助10
6秒前
Dugarrygana发布了新的文献求助10
7秒前
cjzj完成签到,获得积分10
9秒前
CAOHOU的应助被XZM采纳,获得10
9秒前
GJoey发布了新的文献求助10
9秒前
11秒前
11秒前
放青松完成签到,获得积分10
13秒前
13秒前
CodeCraft的应助被空集采纳,获得10
13秒前
14秒前
junyang发布了新的文献求助10
14秒前
苗条梨愁发布了新的文献求助50
14秒前
RONGGE完成签到 ,获得积分10
14秒前
15秒前
renn发布了新的文献求助10
15秒前
haorandu发布了新的文献求助10
16秒前
16秒前
16秒前
852的应助被闫玉坤采纳,获得10
17秒前
牧百川发布了新的文献求助10
17秒前
kuakuapizza完成签到 ,获得积分10
17秒前
molihuakai的应助被野性的苗条采纳,获得10
18秒前
yyychenn发布了新的文献求助10
18秒前
cruise发布了新的文献求助10
18秒前
情怀的应助被lsq108采纳,获得10
18秒前
乾隆发布了新的文献求助10
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648